Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said yesterday.
The warning was another blow, though probably only a glancing one, to Biogen, which is already reeling from the halt in sales of its other multiple sclerosis drug, Tysabri, which was linked to a rare brain infection.
